Immune Effective Score as a Predictor of Response to Neoadjuvant Trastuzumab Therapy and a Prognostic Indicator for HER2-Positive Breast Cancer

Background: HER2-positive breast cancer (BC) is a highly aggressive phenotype. The role of the host immune features in predictive response to anti-HER2 therapies and prognosis in BC has already been suggested. We aimed to develop a predictive and prognostic model and examine its relevance to the cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Xueying, Zhang, Chenyang, Zhang, Henghui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8775173/
https://www.ncbi.nlm.nih.gov/pubmed/35049700
http://dx.doi.org/10.3390/curroncol29010026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8775173/
https://www.ncbi.nlm.nih.gov/pubmed/35049700
http://dx.doi.org/10.3390/curroncol29010026

Ejemplares similares